House Speaker Nancy Pelosi and Treasury Secretary Steven Mnuchin
spoke by phone on Monday about fresh relief measures and were
preparing to talk again on Tuesday.
Comments from officials that a deal was still possible had
lifted Wall Street's main indexes in the previous session,
helping them recoup losses from last week that were sparked by
news that President Donald Trump had contracted COVID-19.
Trump returned to the White House on Monday from the Walter Reed
Medical Center military hospital, but faced fresh backlash for
removing his mask upon his return and urging Americans not to
fear the disease that has killed more than 209,000 in the United
States.
At 6:37 a.m. ET, Dow e-minis <1YMcv1> were up 11 points, or
0.04%, S&P 500 e-minis <EScv1> were down 5.75 points, or 0.17%,
and Nasdaq 100 e-minis <NQcv1> were down 39.75 points, or 0.35%.
Growing political uncertainty in the run up to the presidential
elections and mixed macroeconomic data have increased volatility
in U.S. stocks, with the benchmark S&P 500 <.SPX> and the
tech-heavy Nasdaq <.IXIC> about 5% and 6% below their respective
record highs hit more than a month ago.
Amazon.com Inc <AMZN.O>, Apple Inc <AAPL.O>, Facebook Inc <FB.O>
and Google-owner Alphabet Inc <GOOGL.O>, which have together
dominated Wall Street's recovery from its coronavirus lows in
March, fell in light premarket trading.
The companies have faced intense regulatory scrutiny into their
quest for global market share, and the U.S. House of
Representatives' antitrust report contains a "thinly veiled call
to break up" the companies, Republican Congressman Ken Buck said
in a draft response seen by Reuters.
All eyes later in the day will be on an address by Federal
Reserve Chair Jerome Powell at a virtual meeting of the National
Association for Business Economics, where global central bankers
are likely to present their plans about how much more they can
do to prevent an economic depression.
U.S.-listed shares of BioNTech <22UAy.F> jumped 9.7% after the
European health regulator said it had started a real-time review
of the COVID-19 vaccine being developed by the German biotech
firm and U.S. drugmaker Pfizer Inc <PFE.N>. Pfizer's shares rose
1.7%.
(Reporting by Devik Jain and Sagarika Jaisinghani in Bengaluru;
Editing by Maju Samuel)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|